AML has a heterogenous genetical nature; while about 45% of patients may display normal karyotype, others may show molecular mutations including internal tandem duplications in the FLT3 tyrosine kinase (FLT3-ITD). This evidence concerns the gene FLT3 and acute myeloid leukemia.